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Abstract
Serotonin or 5-hydroxytryptamine (5-HT) is synthesized in both the brain and periph-
eral system, which exert their actions at a wide family of receptors classified as 5-HT
1
 
to 5-HT
7
. Pharmacological, behavioral, and clinical studies involve particularly to the 
5-HT
1A
 receptors (5-HT
1A
-R) - auto-receptors (presynaptic) and heteroreceptors (postsyn-
aptic) - in the control of motivated behavior, and consequently in the physiopathology 
of affective disorders and in the action mechanism of antidepressant drugs. In this way, 
some research support that 5-HT
1A
-R participates in the delayed effect of different types 
of antidepressants, including selective serotonin reuptake inhibitors (SSRIs), and tricy-
clic drugs, principally. The therapeutic effect of serotonergic drugs as the SSRIs, starting 
with the binding to auto-receptors, which produces increases of 5-HT in the synaptic 
cleft as consequence of blockade of serotonin reuptake. While these molecular events 
occur initially, in the long-term are produced plastic changes at neuronal level, as well 
as down-regulation of the 5-HT
1A
-R, which is associated with the therapeutic effects of 
antidepressant drugs. The purpose of this chapter is to analyze and discuss the current 
information about of 5-HT
1A
-R-mediated signaling cascades, the intracellular signaling of 
5-HT
1A
-R, in addition to their expression and pharmacology that are important to treat-
ment of affective disorders symptoms.
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1. Introduction
5-Hydroxytryptamine (5-HT) regulates many important physiological processes, including 
body temperature, sleep, appetite, pain, motor activity, and affective disorders. One type of 
5-HTergic functions is performed by the release of 5-HT into targeted areas and its action 
via at least 16 different pre-and postsynaptic 5-HT receptor (5-HTR) [1]. 5-HTRs are subdi-
vided into seven groups—from 5-HT
1
-R to 5-HT
7
-R—according to their distribution, molecu-
lar structure, cell response, and function. Except for the 5-HT
3
-Rs, which are ligand-gated 
ion channels, all other 5-HTR are G-protein-coupled receptors that influence different trans-
duction pathways (Table 1). 5-HT
1A
-R auto-receptors located on the soma of 5-HTergic neu-
rons are key components of the negative feedback loop that inhibits neuronal signaling and 
5-HT release [2], while 5-HT
1A
-R heteroreceptors located on postsynaptic 5-HTergic and non-
5-HTergic neurons [3, 4], particularly those in the limbic system, are involved in emotional 
states.
2. Distribution and ontogeny of the 5-HT
1A
-R
The 5-HT can interact with different types of receptors, whose effect depends on the activa-
tion of different subtypes and location of these [1, 3] (Table 1). In this sense, the use of such 
techniques as ligand binding, immunohistochemistry, and hybridization in situ in the brains of 
the rat, mouse, cat, and human has reported significant levels of 5-HT
1A
-R in almost all regions 
of the brain [5–9]. A study performed in cats used positron emission tomography (PET) and 
2′-methoxyphenyl-(N-2′-pyridinyl)-p-fluoro-benzamidoethyipiperazin marked with fluorine 
(MPPF [18F]) in combination with in vitro autoradiography with [3H] MPPF, 8-hydroxy-2-(di-
n-propylamino)tetralin ([3H] 8-OH-DPAT) and [3H] paroxetine, to visualize the distribution 
of the 5-HT
1A
-R. These showed high levels of expression in the hippocampus, cingulate, sep-
tum, infralimbic cortex, and raphe nuclei, with low levels being detected in the cerebellum [9]. 
However, studies with PET using [11C] WAY-100635 reported some regional heterogeneity of 
the 5-HT
1A
-R in the human cerebellum [10]. The absence of 5-HT
1A
-R expression was observed in 
Receptor family Subtype Mechanism Cellular response
5-HT
1
1A, 1B, 1D, 1E, 1F Adenylate cyclase Inhibitory
5-HT
2
2A, 2B, 2C Phospholipase C Excitatory
5-HT
3
3A, 3B, 3C Ligand-gated ion channel Excitatory
5-HT
4
54 Adenylate cyclase Excitatory
5-HT
5
5A, 5B Adenylate cyclase Inhibitory
5-HT
6
56 Adenylate cyclase Excitatory
5-HT
7
Adenylate cyclase Excitatory
Table 1. Classification and mechanism of the 5-HT receptor.
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the cerebellar white matter, while the other regions displayed detectable levels of this receptor. 
On the other hand, studies of the cellular distribution of this receptor and its messenger ribo-
nucleic acid (mRNA) have reported that approximately 60% of all glutamatergic cells express 
the transcript 5-HT
1A
-R, and about 25% of cells that express the enzyme glutamate decarboxyl-
ase (GAD) contain mRNA for 5-HT
1A
-R [5]. In addition, studies using immunohistochemistry, 
in vitro autoradiography with [3H] 8-OH-DPAT, and in situ hybridization have reported mRNA 
and protein expression for the 5-HT
1A
-R in the pyramidal neurons of layer 2 of the prefrontal, 
insular, and occipital cortex [9], but labeling with [3 H] 8-OH-DPAT is only detected the layers 
1 and 2 of the prefrontal and occipital cortex and in the pyramidal neurons of the cloister and 
the anterior olfactory nucleus. Neurons of the hippocampal CA1 region expressed the mRNA 
of the 5-HT
1A
-R, and [3H] 8-OH-DPAT labeling was observed in the stratum oriens and stratum 
radiatum. Low receptor expression was observed in CA3 pyramidal neurons, but the granule 
neurons in the dentate gyrus contained moderate concentrations of this receptor.
Turning now to the ontogeny of the 5-HT
1A
-R, immunohistochemistry has shown that almost 
all neurons of the hippocampus begin to express the 5-HT
1A
-R at the end of mitosis [11]. It is 
well known that at day 5 of postnatal age (P5), this receptor is expressed mainly in the cell 
bodies, while at day P10 it appears in the cell bodies and proximal apical dendrites. At the end 
of neuronal maturation (P21), a relatively scarce distribution is seen in the dendrites of the 
stratum radiatum and oriens of the hippocampus. During the early postnatal development 
of the hippocampus, glial cells that are positive to S100 (protein saturated ammonium sul-
fate soluble) and glial fibrillary acidic protein (GFAP) temporarily express the 5-HT
1A
-R and 
more than 90% of astrocytes that are positive to S100 in CA1, CA3, and the dentate gyrus also 
show moderate immunoreactivity to the 5-HT
1A
-R in P7, though this decreases sharply in P16. 
Although the specific distribution of the 5-HT
1A
-R has been studied in different brain regions, 
this does not ensure that receptor signaling activity will always be proportional to the levels 
of receptor expression. 5-HT
1A
-R signaling in neurons is important for functionality, and this 
intracellular effect is regulated by the coupling of second messengers.
3. Presynaptic and postsynaptic 5-HT
1A
-R and their signaling effects
The main electrophysiological response to the activation of the 5-HT
1A
-R in neurons is mediated 
by the hyperpolarization of K+ channels [12, 13], which attenuates the propagation of action 
potentials, causing a consequent decrease in the release of the neurotransmitter. The hyperpo-
larizing effect is observed in both pre- and postsynaptic terminals; however, the desensitization 
profiles of those receptors and molecules activated in the pre- and postsynaptic terminals seem 
to differ. One of the mechanisms that cause desensitization of G-protein-coupled receptors is 
internalization, and studies have demonstrated the internalization (i.e., transfer of the plasmatic 
membrane in the cytoplasm) of the 5-HT
1A
 auto-receptors in the dorsal raphe nucleus (DRN) 
of rats after acute treatment with the specific 8-OH-DPAT agonist to the 5-HT
1A
-R, or with 
recapture inhibitors of the 5-HT (selective inhibitors of serotonin reuptake, SSRIs). Although 
this phenomenon has not been observed in the hippocampus, we know that in this structure 
the 5-HT
1A
-Rs are located in the soma and dendrites of neurons (heteroreceptors) [14]. The 
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SSRIs in the presynaptic terminals, in turn, increase the release of 5-HT, which binds to the 
5-HT
1A
-R auto-receptors present in the soma of the raphe neurons, thus inhibiting neuronal fir-
ing. Subsequently, these auto-receptors are internalized, causing the end of 5-HT
1A
-R signaling 
in the presynaptic neurons, and again at onset of the 5-HT release of the rape neurons in the 
synapse with the dendritic terminals of the postsynaptic neurons. In the absence of the 5-HT
1A
 
auto-receptors, the 5HT released binds only to the postsynaptic 5-HT
1A
-R, thereby eliciting the 
anxiolytic effect of the SSRIs [15]. On the other hand, agonists to 5-HT
1A
-R, such as buspirone 
or flesinoxan, show an antidepressant effect, probably due to the desensitization of the 5-HT
1A
 
auto-receptors [16, 17]. Thus, the acute agonist treatment has its effect due to interaction with 
the auto-receptors present in the soma of the raphe neurons. The hyperpolarizing effect of the 
activation of this auto-receptor inhibits the release of 5-HT in the presynaptic terminal. It has 
been reported that under this treatment, the free or excess agonist can activate the postsynaptic 
(dendritic) 5-HT
1A
-R, resulting in the inhibition of postsynaptic neurons. Thus, an overstimula-
tion of the receptor by an agonist causes desensitization and internalization of the 5-HT
1A
-R in 
raphe neurons, but not in postsynaptic neurons. The absence of 5-HT
1A
 auto-receptors in the 
presynaptic raphe terminal facilitates neural firing by blocking inhibition by 5-HT, which is 
attached to the 5-HT
1A
-R in the postsynaptic neurons and causes the anxiolytic effect.
The activation of both pre- and postsynaptic 5-HT
1A
-R and their subsequent signaling seems 
to differ in at least one biochemical pathway. It has been shown that HN2-5 cells derived from 
neurons in the hippocampus, as well as in organotypic cultures of slices of the hippocampus, 
which are agonists to the 5-HT
1A
-R, stimulate the protein kinase pathway activated by mito-
gen (MAPK) [18]. However, in the raphe-derived cell line RN46A, activation of this receptor 
by agonists inhibits the basal activity of the MAPK pathway [19]. Nonetheless, it has been 
reported that activation of the 5-HT
1A
-R located both pre- and postsynaptically with the ago-
nist inhibits intracellular cyclic adenosine monophosphate (cAMP) [20]. There are also reports 
that activation of 5-HT
1A
-R in a postsynaptic neuron-derived cell line and in non-neuronal 
cells promotes synthesis of phospholipase C (PLC), but this response has not been reported in 
presynaptic (serotonergic) or raphe-derived neurons [20, 21].
4. Aberrant 5-HT
1A
-R expression, anxiety and depression disorders
In recent decades, such psychiatric disorders as anxiety (mainly generalized anxiety) and 
depression (mainly severe) have increased in prevalence and are now responsible for 3.12 
and 6.86%, respectively, of years lived with disability (YLDs), according to estimates by the 
Global Burden of Diseases in 2015. Anxiety is a normal human emotion that allows us to 
respond to everyday stress situations, where the stressor—work, for example—can be identi-
fied. However, anxiety becomes a disorder when it no longer allows the individual to remain 
functional in her/his daily activities and when no trigger can be identified [22]. Both anxiety 
and depression have been attributed to a varied etiology that includes the person’s social, 
economic, family, employment and academic condition, combined with the persistence of 
an inherent biological factor. In this sense, the findings of clinical and preclinical studies 
have identified a dysfunctionality of the serotonergic system associated with low  availability 
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of L-tryptophan (a precursor of 5-HT), low concentrations of 5-hydroxyindoleacetic acid 
(5-HIIA)—the main metabolite of 5-HT in the cerebrospinal fluid—a reduction in the synthe-
sis, release, recapture, and metabolism of 5-HT, a decrease in the density of 5-HT
1A
-R pre- and 
postsynaptic, low neural activity in brain areas involved in regulating the emotions (such as 
the septum and prefrontal cortex), factors that increase the propensity (serotoninergic vulner-
ability) to suffer mood disorders like anxiety and depression. This is reinforced by the fact 
that serotonergic antidepressant treatments are prescribed to reverse these types of altera-
tions [23–25]. In addition, functional brain imaging and postmortem studies of the limbic 
structures of depressed patients—which are responsible for integrating the emotions, and 
include the striatum, amygdala, and frontal cortex—have reported a low capacity for recap-
ture 5-HT coupled with a decrease in the expression of 5-HT (5-HTT) transporters, which are 
responsible for recapturing the unused 5-HT in the 5-HT synapse and so regulate the mag-
nitude and duration of serotoninergic neurotransmission [26]. Alterations of this kind in the 
5-HTT have also been detected in patients with major depression using PET, which reveals a 
low capacity for 5-HT recapture in the thalamus, an area involved in controlling cortical excit-
ability that contributes to establishing anxiety in patients so affected [27].
In addition, the involvement of deregulation of pre- and postsynaptic 5-HT
1A
-R in anxiety 
and depression is widely known, since it has been observed in patients with panic disorder 
by PET studies. There, reports indicate a reduction in the availability of both pre- and post-
synaptic 5-HT
1A
-R in brain areas that regulate cognitive and emotional responses, such as 
the raphe, the orbitofrontal cortex, the temporal cortex, and the amygdala [28]. In support of 
this, preclinical studies have reported that knockout mice for 5-HT
1A
-R present an anxious 
phenotype that includes observations of such behaviors as a decrease of thigmotaxis (i.e., 
exploratory activity in central areas of an open field), increased fear in aversive environments, 
increased reactivity to stress, autonomic activation, and neuroendocrine alterations in mod-
els of experimental anxiety using the open-field, elevated-zero maze, and novel-object tests. 
However, an antidepressant-like effect has been observed in the tail suspension model of 
experimental depression, more markedly in females than in males. This is not associated with 
morphological abnormalities in brain tissues or changes in cell bodies or 5-HTergic fibers, nor 
is there evidence of changes in brain levels of 5-HT and 5-HIIA in the striatum, dorsal raphe, 
or frontal cortex [29, 30], though there is an increase in the turnover of 5-HT [31] and the fir-
ing of 5-HTergic neurons [32] in knockout mice to 5-HT
1A
-R. However, the possibility of such 
long-term changes cannot be discarded [33]. This situation can be interpreted as a disinhibi-
tion of 5-HTergic neuronal activity that increases the release of 5-HT in limbic areas, causing 
the establishment of anxiety through its interaction with other receptor subtypes, but without 
modifying levels of 5-HT or its metabolite, since the amount of stored 5-HT greatly exceeds 
the extracellular 5-HT content.
In support of this, differences in the function of the pre- and postsynaptic 5-HT
1A
-R in dif-
ferent brain areas seem to be decisive in establishing anxiety and depression, given that 
stimulation of the postsynaptic 5-HT
1A
-R in the dorsal hippocampus and amygdala pro-
duces anxiogenic effects, while anxiolytic effects are seen in areas such as the middle and 
dorsal raphe (where the 5-HT
1A
 auto-receptors are located) [33–35]. In contrast, stimulation 
of the presynaptic receptors produces anxiolytic effects by suppressing 5-HTergic neuronal 
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activity with the resulting decrease of 5-HT in axonal terminals of limbic areas [36]. These 
findings suggest that there are differences in the role played by pre- and postsynaptic 
5-HT
1A
-R receptors in regulating emotions. This may be reflected in the fact that acute 
administration of antidepressants causes a reduction in neural activity due to the imme-
diate stimulation of the 5-HT
1A
 auto-receptors, while chronic antidepressant treatments 
cause desensitization and, consequently, the downregulation of the 5-HT
1A
 auto-receptors, 
though with no changes in postsynaptic 5-HT
1A
-R. This leads to the recovery of 5-HTergic 
neuronal activity, which matches the long latency to the onset of the therapeutic effects of 
SSRIs antidepressants.
It is important to note that mice require proper 5-HTergic signaling through 5-HT
1A
-R stimu-
lation of the prosencephalon during the early postnatal period as this produces lasting chemi-
cal and structural changes in the brain that are essential for effective response behaviors in 
the face of normal anxiety during adulthood [37]. Thus, clinically effective antidepressant or 
anti-anxiety treatments must stimulate the 5-HT
1A
 auto-receptors with direct agonists (such 
as buspirone) or indirect agonists like fluoxetine to obtain therapeutic efficacy. This suggests 
that in both the developmental and adult stage efficient activation of the 5-HT
1A
 auto-recep-
tors can produce changes that decrease expressions of pathological anxiety.
Donaldson et al. [38] reported that a decrease in the 5-HT
1A
 auto-receptors in the 21st post-
natal leads to increased long-term anxiety levels but does not modify depressive behaviors. 
In this regard, lifelong abolition of the 5-HT
1A 
auto-receptors suffices to increase anxiety 
behaviors in adult mice [39], though without necessarily affecting depressive-like behaviors 
in the forced swimming test [40]. Based on these results, it has been suggested that 5-HT
1A
 
auto-receptors are involved in establishing anxious and depressive phenotypes, while the 
heteroreceptor is implicated in the depressive phenotype observed in experimental tests of 
depression [40]. Moreover, Albert and François [41] suggest that a reduction in the activ-
ity of postsynaptic receptors is involved in anxiety and that an increase in the transcrip-
tion of 5-HT
1A
 auto-receptors is associated with both depression and resistance to chronic 
treatment with SSIR drugs [41]. Hence, the reduced expression of the auto-receptors with 
no modification of postsynaptic 5-HT
1A
-R expression is enough to produce depression-like 
behaviors in mice [42].
5. Therapeutic agents that function by regulating 5-HT
1A
-R signaling
5-HT
1A
-R is involved in the pathology and treatment of mental disorders, such as anxiety 
and depression [23, 43, 44]. Several studies have suggested that the 5-HT
1A
-Rs are potential 
targets for these psychiatric disorders [45–49]. In this regard, agonists (total and partial) to the 
5-HT
1A
-R have shown antidepressant and anxiolytic properties and have been employed as 
adjunct treatments to improve the therapeutic action of several antidepressant and anxiolytic 
drugs in several preclinical and clinical studies [50–53]. They offer a different pharmacologi-
cal mechanism from that of the monoamine oxidase inhibitors (IMAO), tricyclic drugs, SSIRs, 
and other antidepressants.
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Buspirone is perhaps the most widely studied partial 5-HT
1A
-R agonist. It belongs to the 
chemical class of the azapirones [54, 55] and has been used primarily due to its anxiolytic 
effects and absence of side effects such as sedation and dependence that are often associated 
with benzodiazepines [56]. It is also utilized to treat patients who are resistant to the SSRI
S
, 
due to its capacity to stimulate the release of catecholamines [57]. In this regard, a clinical trial 
carried out with ambulatory patients diagnosed with generalized anxiety disorder (GAD) 
found that after weeks 3 and 4, buspirone showed efficacy in relieving patients’ symptoms 
with a therapeutic effect comparable to that of lorazepam. Also, after discontinuing this ther-
apy, the individuals treated with buspirone showed no withdrawal symptoms, while those 
medicated with lorazepam saw their symptoms worsen in week 9 after ceasing treatment [58]. 
Similarly, buspirone (15 mg/day) prescribed for 4 weeks to ambulatory patients with GAD 
produced a significant reduction of anxiety symptoms compared to alprazolam. Moreover, 
the patients treated with buspirone experienced fewer adverse effects and symptoms of absti-
nence than those who received alprazolam [59]. The anxiolytic properties of buspirone have 
been confirmed in animal models. For example, in a study conducted with Swiss Albino mice 
that received buspirone at 2.5 and 5 mg/kg, i.p., the drug significantly increased the number 
of step-through by 46 and 61%, respectively [60]. This demonstrates that buspirone is effec-
tive in treating anxiety disorders without causing adverse effects or signs of benzodiazepine 
dependence.
Gepirone is another component of the class of the azapirones that has shown antidepressant 
properties [61] due to its partial 5-HT
1A
-R antagonism, which improves 5-HTergic activity 
[62]. The structure of this azapirone is similar to that of buspirone, and it has similar anxio-
lytic properties that have been identified in clinical studies [63, 64]. But it also has antidepres-
sant action. In a study of patients with major depressive disorder (DDM), prolonged-release 
gepirone (60–80 mg/day) administered for 3 weeks produced a significant reduction in total 
HAM-D17 scores (Hamilton Depression Scale) compared to a placebo group, thus improv-
ing the symptomatology of patients [65]. Similarly, gepirone (40–80 mg/day) prescribed for 8 
weeks improved the sexual function of male patients diagnosed with DDM, in addition to its 
antidepressant action [66].
Tandospirone is a partial 5-HT
1A
-R agonist that has been shown to have antidepressant effects. 
In a study with male Sprague-Dawley rats, chronic treatment (28 days) with tandospirone at 
10 mg/kg inhibited changes induced by psychosocial stress in the neurogenesis of the dorsal 
and ventral hippocampus, thus producing a type of antidepressant effect. It has been sug-
gested that chronic administration of tandospirone desensitizes the 5-HT
1A
-R in the raphe. 
This decreases self-inhibition mediated by the somatodendritic receptor and, consequently, 
increases the firing rate and release of 5-HT [67].
Brexpiprazole is a second-generation antipsychotic that exerts partial antagonism to the 
5-HT
1A
-R and D2. A study in adults diagnosed with DDM, but inadequate responses to 
antidepressants, showed that brexpiprazole as an adjunct therapy improved patients’ 
symptoms. In that research, a series of drugs—escitalopram, fluoxetine, paroxetine, sertra-
line, duloxetine, and venlafaxine—all significantly improved scores on the Clinical Global 
Impressions Scale (CGI-I scale), Zung Self-Rating Depression Scale (SDS), and HAM-D17 
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scale when administered jointly with brexpiprazole (2 mg) for 6 weeks. Improvement was 
remarkable from the first week of treatment [68]. Finally, flesinoxan is a phenylpiperazine 
derivative initially developed as an antihypertensive [69]. This drug has total antagonism to 
5-HT
1A
-R with high affinity [70]. Various studies have demonstrated its antidepressant prop-
erties, particularly in treatment-resistant DDM patients [71]. For example, in a double-blind, 
placebo-controlled and fixed-dose study of treatment-resistant DDM patients, flesinoxan 
(1.2 mg/day) administered for 6 weeks improved scores on the HAM-D17, Montgomery-
Asberg Depression Rating Scale (MADRS) and CGI scales with improvement in subjects’ 
mood. Nausea and dizziness were the most common side effects reported [72]. The thera-
peutic effects of flesinoxan have also been reported in animal models. In research with male 
Sprague-Dawley rats after olfactory bulbectomy, subjects were given flesinoxan (1 and 3 mg/
kg, s.c.) for 17 days. They presented reduced total immobility time on the forced swimming 
test [73]. This therapeutic action may be associated with the desensitization effect of the 
5-HT
1A
-R in the nucleus of the dorsal raphe as an action mechanism [71].
The antidepressant activity of agonists to the 5-HT
1A
-R in presynaptic and postsynap-
tic neurons has been widely reported. Studies using the model of experimental learned 
helplessness in relation to depression have reported that stimulation of the 5-HT
1A
-R with 
8-OH-DPAT at dosages of 0.03, 0.06, 0.125, 0.25, and 1 mg/kg i.p. for 5 days shows an anti-
depressant effect. To explore the role of the pre- and postsynaptic 5-HT
1A
-R, in that study, 
8-OH-DPAT (0.1 and 1 µg/0.5 µl) was microinjected into the raphe and septum. While this 
showed an antidepressant effect when microinjected into the septum, no such effect was 
seen in the raphe of male rats [74]. This indicates that stimulation of the postsynaptic 5-HT
1A
 
receptors is responsible for establishing the antidepressant effect caused by 5-HT
1A
-R ago-
nists when managed through a systemic pathway, since stimulation of the 5-HT
1A
 somato-
dendritic auto-receptors in the raphe inhibits the release of 5-HT and the electrical activity 
of the raphe [75].
In recent years, administration of vilazodone has shown antidepressant [75, 76] and anxiolytic 
effects by eliminating physical and somatic symptoms in women with generalized anxiety 
disorder, after 8 weeks of treatment at daily doses of 20–40 mg [77, 78]. This effect is due to 
the action mechanism of this SSRI, which is a partial agonist of postsynaptic 5-HT
1A
 receptors. 
In addition, it desensitizes 5-HT
1A
 auto-receptors in the raphe more quickly than fluoxetine 
or paroxetine [79], is 30 times more powerful than serotonin transporter (SERT), and causes a 
larger increase of extracellular 5-HT in the ventral hippocampus and frontal cortex [80]. These 
facts justify the short latency to the appearance of therapeutic effects. Similar data have been 
reported in models of experimental anxiety using ultrasonic vocalizations. Observations sug-
gest that vidazolam produces an anxiolytic effect that can be reversed by coadministration 
with an antagonist of the presynaptic 5-HT
1A
 receptors such as WAY-100635.
This substance also produced an anxiolytic effect in the model of predator-induced stress at 
doses of 20–40 mg/kg and in the defensive burial model at doses of 10–40 mg/kg. However, 
no anxiolytic effect was seen in the elevated arms maze model [81]. Antidepressant effects at 
doses of 1 mg/kg were found in models of experimental depression based on the forced swim-
ming and tail suspension tests [82].
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6. Recent advances in the use of serotonin-norepinephrine reuptake 
inhibitors (SNRIs) for treating affective disorders
Affective disorders are characterized by vigorousness in neurotransmission pathways at the 
cerebral level with reductions in serotonergic, noradrenergic, and dopaminergic concentra-
tions, among other neurochemical and neuroanatomical changes. Consequently, therapeutic 
strategies designed to treat affective disorders include combinations of drugs and, in other 
cases, chemical compounds that act on one or more neurotransmission systems [83]. In this 
way, serotonin-norepinephrine reuptake inhibitors (SNRIs) have the capacity to block sero-
tonin and noradrenalin reuptake in the brain, and so have been used successfully to treat 
such affective disorders as depression, emotional disorders like anxiety, and other illnesses 
related to the control of overweightness, fibromyalgia, peripheral diabetic neuropathic pain, 
and attention deficit-hyperactivity disorders, among others (Table 2).
The SNRIs were introduced into therapeutic use in the USA in 1993 under the name venla-
faxine, a chemical compound included in a group of molecules named phenylethylamines, 
whose action mechanism principally involves the reuptake inhibition of serotonin and nor-
adrenaline, though a lower degree of dopamine reuptake inhibition has also been reported. 
Through their dual action, these substances quickly increase concentrations of both neu-
rotransmitters, apparently producing better therapeutic actions in major depression disor-
ders than conventional antidepressant drugs that act upon only a single neurotransmission 
system. But SNRIs can produce side effects that include loss of appetite, reduced body weight 
and sleep, fatigue, headaches, nausea/vomiting, sexual dysfunction, and urinary retention, 
among others. To a lesser degree, they can also produce anxiety and high blood pressure. 
It is important to point out that some patients treated with SNRIs have increased suicidal 
thoughts, though this is still subject to controversy [84]. Despite their side effects, SNRIs 
are used frequently to control several depressive disorders due to their therapeutic efficacy. 
Active compound Therapeutic use Reference
Venlafaxine MDD, AD, syndrome of chronic pain, 
BDD
[85, 86]
Desvenlafaxine MDD in adult patients [89]
Duloxetine MDD, DPNP, fibromyalgia [96, 104, 107]
Atomoxetine ADHD in adults and pediatric 
patients under 6 years old
[103, 108]
Sibutramine Treatment of obesity [106]
Milnacipran MDD, fibromyalgia [85, 105]
Levomilnacipran MDD, AD in adult patients [90]
Abbreviations: MDD, major depression disorder; BDD, bipolar depression disorder; AD, anxiety disorder; DPNP, 
diabetic peripheral neuropathy pain; ADHD, attention deficit hyperactivity disorder.
Table 2. Principal serotonin-norepinephrine reuptake inhibitors and their therapeutic uses.
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Indeed, in some cases they work better than classic antidepressant drugs (e.g., SSRIs and tri-
cyclic drugs) in certain groups of patients. For example, a clinical study of patients diagnosed 
with major depression disorder (aged 18–65) found remission of symptoms after 24 weeks 
of treatment with venlafaxine (initial dose of 75 mg/day, maximum dose of 225 mg/day) and 
milnacipran (50 mg twice a day), with a greater effect than that produced by 20 mg/day of the 
SSRI paroxetine [85]. However, in patients diagnosed with Alzheimer’s and major depres-
sion disorders, the SSRIs sertraline and venlafaxine had a greater effect than the tricyclic 
antidepressant desipramine, all at doses of 150 mg/day during 12 weeks of treatment [86]. 
In a randomized, double-blind, parallel group study that evaluated the effect of long-term 
treatment (12 weeks) with venlafaxine in adult patients, there was a significant reduction of 
depressive symptoms compared to patients under the same conditions but treated with a 
lithium monotherapy [87]. Another SNRI used to treat major depression disorder is desven-
lafaxine [88]. An integrated analysis of the efficacy of this drug found that treatment with 50 
and 100 g/day reduced depression symptoms in patients diagnosed with major depression 
disorder compared to a placebo group [89].
Similarly, treatment with levomilnacipran (40–120 mg) in patients aged 18–80 diagnosed with 
some depression disorder, significantly reduced symptoms after 8–10 weeks of treatment 
[90]. These data show that the effect of SNRIs in treating major depression disorders depends 
on the characteristics of patients and the dosage schedule. One double-blind, controlled, ran-
domized study compared two treatment schedules with venlafaxine: one fixed (75 mg/day) 
the other flexible (75–225 mg/day). It found that the fixed program gave a better response to 
this antidepressant treatment than the flexible approach [91]. Similarly, the use of SNRIs in 
young depressed patients (7–18) did not produce better therapeutic effects than a placebo 
treatment, though duloxetine has shown therapeutic potential in such patients [92]. A meta-
analysis of the efficacy of venlafaxine, duloxetine, fluoxetine, and imipramine in children and 
adolescents found that SNRIs and tricyclic antidepressants do not seem to offer a significant 
advantage in treating major depression disorder in this population, as only fluoxetine pro-
duced an adequate therapeutic effect in those patients [93].
SNRIs are also often used to treat depressive symptoms associated with menopause. It is well 
known that in this biological phase, women are more susceptible and vulnerable to socio-
environmental factors that predispose them to develop emotional and affective disorders [94]. 
Menopausal women diagnosed with major depression disorders and vasomotor symptoms 
treated with duloxetine for 8 weeks experienced a reduction in their depressive and vasomo-
tor symptoms, positive anxiolytic effects, and improved sleep quality, so it is believed that 
SNRIs may be an effective therapeutic option for treating mood and emotional disorders, as 
well as the more general symptoms associated with menopause [95]. In addition to its role as 
an effective treatment for major depression disorders associated with menopause, duloxetine 
is used to control other symptoms, such as hot flashes and anxiety [96]. Meanwhile, meno-
pausal women treated with venlafaxine (75–300 mg/day) or fluoxetine (20–60 mg/day) felt a 
reduction in their depressive symptoms after 6 weeks of treatment, with no significant dif-
ferences between these two antidepressants [97]. Administration of desvenlafaxine (50, 100, 
or 200 mg/day) to peri- and postmenopausal women also reduced depressive symptom com-
pared to a placebo [98].
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7. Mechanism of action of selective serotonin reuptake inhibitors (SSRIs) 
and affective disorders
The action mechanism of SSRIs consists in inhibiting the 5-HT transporters (SERT) in the 
soma of raphe dorsal neurons (Figure 1). It has been shown that SSRIs, such as fluoxetine, 
that have an antidepressant effect possess a mechanism that inhibits SERT, thus increasing 
the availability of 5-HT in the synaptic cleft. This is accompanied by an increase in 5-HTergic 
neurotransmission associated with the establishment of the antidepressant effect [99]. This 
pharmacological effect is not immediate, suggesting that the 5-HT
1A 
transporter blockade, per 
se, does not produce therapeutic effects during acute treatment, since in the first week of 
antidepressant therapy with SSRIs increases 5-HTergic neurotransmission due to the avail-
ability of 5-HT, which causes an overstimulation of the 5-HT
1A
 auto-receptors, located in the 
cell body and dendrites of neurons in the raphe. Therefore, its neuronal activity, which is in 
charge of releasing 5-HT, is reduced in limbic areas, though we know that treatment with 
SSRI antidepressants requires 2–3 weeks to establish its therapeutic effect, because regula-
tion of 5-HTergic neurotransmission in depressed patients requires the desensitization and 
subsequent internalization of the 5-HT
1A
 auto-receptors of presynaptic neurons that eliminate 
the negative feedback on the raphe, thus increasing its neuronal activity and normalizing the 
release of 5-HT to the synaptic cleft that, finally, translates into an antidepressant effect.
The postsynaptic mechanism and cellular signaling of the 5-HT
1A
-R in relation to mood control 
are very complex. In this regard, it has been reported that some accompany the establish-
ment of the therapeutic effect of SSRI antidepressants. One of the most important effects is 
the desensitization of the 5-HT
1A
 auto-receptors. Normally in 5-HTergic neurotransmission, 
once the 5-HT is released into the synaptic cleft, it mainly has a three-point coupling. The 
Figure 1. Mechanism of SSRIs: the 5-HT transporters (SERT) in the soma of raphe dorsal neurons; modified according 
to Garcia-Garcia et al. [40].
Association of 5-HT1A Receptors with Affective Disorders
http://dx.doi.org/10.5772/intechopen.68975
157
first is to the postsynaptic serotonergic receptors, mainly 5-HT
1A
. These receptors are coupled 
to the inhibition of protein G (Gi/o) and the consequent decrease in AMPc synthesis due to 
the inhibition of adenylate cyclase which, in conjunction with other second messengers, are 
responsible for activating the opening of ion channels, including Na+ and K+, for its input and 
output, respectively (Figure 2). This contributes to the hyperpolarization of the postsynaptic 
neurons so that they can go with the flow of neural inhibition. The second coupling is with the 
SERT, which are responsible for the reuptake of unused synapse 5-HT, which is returned to the 
presynaptic neuron through recycling, where it is stored for later release or to be metabolized 
to reset the synthesis of 5-HT. The energetic cost of its production is very high. The third cou-
pling is with the 5-HT
1A
 auto-receptors and, to a lesser extent, 5-HT
1B
 and 5-HT1D. This causes 
inhibition of the opening of Ca2+ channels from the presynaptic neuron, which then inhibits 
the release of 5-HT into the synaptic cleft, thus regulating the intensity and duration of the 
nerve impulse from the presynaptic neuron (i.e., negative feedback or self-inhibition), mainly 
in neurons of the raphe, exerting the end the signaling of the presynaptic neurons and the 
resumption of the release of 5-HT neurons from the raphe to the postsynaptic neurons through 
the limbic areas [100]. In this context, chronic administration of SSRIs induces internalization 
of the 5-HT
1A
 auto-receptors and the neurons of the raphe [101], since the increase in the avail-
ability of 5-HT in the cleft overstimulates those auto-receptors while also desensitizing and 
internalizing them. This process is associated with the phosphorylation of the carboxylic chain 
Figure 2. Model of the transduction pathways that may be activated by the 5-HT
1A
-R; modified according to Polter and 
Li [100].
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and the third intracellular loop of the receptor. The absence of 5-HT
1A
 auto-receptors induces 
the binding of 5-HT only to postsynaptic 5-HT 1A receptors, which in turn triggers the antide-
pressant effect of SSRIs, though only after 2–3 weeks of treatment. However, this desensitiza-
tion effect on the auto-receptors depends on the type of SSRIs administered, as it has not been 
observed when sertraline is administered chronically in humans [102].
8. Conclusion
Multiple antidepressant drugs are known to function through the 5-HT
1A
-R. New findings 
related to dysfunctions in the serotoninergic system, specifically in both pre- and postsynaptic 
5-HT
1A
-R in the signaling pathways that modulate the 5-HT
1A
-R, demonstrate that 5HTergic 
alterations—whether in the expression or functionality associated with such disorders as anxi-
ety and depression, and their subsequent association with alterations in signaling pathways 
that indirectly modulate and involve survival and neuronal development—can interfere with 
responses to antidepressant treatment. However, we require additional studies that accurately 
identify signaling mechanisms in different brain areas and differentiate their functions between 
the pre- and postsynaptic 5-HT
1A
-R present in intact animals and animals subjected to clini-
cally effective antidepressant and anti-anxiety treatments. Since we know that differences in 
the distribution of receptors in the brain determine the physiological and behavioral functions, 
a better understanding of the underlying mechanisms associated with abnormal activity of the 
5-HT
1A
-R will contribute to the search for novel therapeutic strategies that explore new ways 
of enhancing treatment of the most common psychiatric disorders around the world, includ-
ing those of anxiety and depression, which severely impair the quality of life of individuals.
In general, the participation of the 5-HT
1A
-R in psychiatric disorders such as anxiety and depression 
has been widely explored in numerous clinical studies and animal models. All findings seem to indi-
cate that including agonist components to the 5-HT
1A
-R in drug treatment of individuals with anxiety 
and depression is a promising option for improving the efficiency and implementation of the thera-
peutic effect of conventional drugs. It is important to emphasize that stimulation of the 5-HT
1A
-R 
activates indirect signaling mechanisms that have not yet been studied, so further research is neces-
sary to explore possible alternative signaling mechanisms that accompany the establishment of the 
antidepressant effects mediated by 5-HT
1A
-R. Finally, in order to better understand the etiology of 
many disorders of brain development and advance in the elaboration of drugs that target 5-HT
1A
-R, 
it is important to study the profile of this receptor’s activity in brain signaling during development.
In summary, there is ample clinical evidence to support the idea that SNRIs may be used to 
treat major depression disorder and other psychiatric disorders in certain groups of patients. 
However, the scarcity of controlled clinical studies and the wide age range of patients 
included in existing work, in addition to the scarce comparisons of the effects of SNRIs and 
classic antidepressant drugs (e.g., SSRIs and tricyclic antidepressants), raise the challenge of 
determining whether SNRIs produce greater, similar, or lower therapeutic effects than tradi-
tional therapeutic schedules. Nonetheless, the data currently available open doors for future 
research designed to explore new therapeutic options that will benefit patients with major 
depression disorders or other affective or emotional alterations.
Association of 5-HT1A Receptors with Affective Disorders
http://dx.doi.org/10.5772/intechopen.68975
159
Acknowledgements
The writing of this chapter was made possible, in part, by funding from the Programa de Apoyo 
a la Mejora de las Condiciones de Producción de los Miembros del SNI y SNCA (PRO-SNI) 2017. 
The sixth author received financial support from Consejo Nacional de Ciencia y Tecnología 
(CONACyT) for postdoctoral studies at the University Center of Los Lagos, Universidad de 
Guadalajara (Laboratory of Biomedical Sciences/Histology). The fourth author received fel-
lowship from CONACyT for postgraduate studies in Neuroethology Reg. 297560.
Author details
Cesar Soria-Fregozo1*, Maria Isabel Perez-Vega1, Juan Francisco Rodríguez-Landa2, León 
Jesús Germán-Ponciano3, Rosa Isela García-Ríos4 and Armando Mora-Perez1
*Address all correspondence to: csoria@culagos.udg.mx
1 Laboratory of Biomedical Sciences/Histology, University Center of Los Lagos, University of 
Guadalajara, Lagos de Moreno, Jalisco, Mexico
2 Laboratory of Neuropharmacology, Institute of Neuroethology, University Veracruzana, 
Xalapa, Veracruz, México
3 Postgraduate in Neuroethology, Institute of Neuroethology, Universidad Veracruzana, 
Xalapa, Veracruz, México
4 Department of Health Sciences, University Center of Tonalá, University of Guadalajara, 
México
References
[1] Nichols DE, Nichols CD. Serotonin receptors. Chemical Review. 2008;108:1614-1641. 
DOI: 10.1021/cr078224o
[2] Hjorth S, Bengtsson HJ, Kullberg A, Carlzon D, Peilot H, Auerbach SB. Serotonin auto-
receptor function and antidepressant drug action. Journal of Psychopharmacology. 
2000;14:177-185. DOI: 10.1177/026988110001400208
[3] Hoyer D, Hannon JP, Martin GR. Molecular, pharmacological and functional diversity 
of 5-HT receptors. Pharmacology Biochemistry and Behavior. 2002;71:533-554. DOI: 
10.1016/S0091-3057(01)00746-8
[4] Lemonde S, Turecki G, Bakish D, Du L, Hrdina PD, Bown CD, Sequeira A, Kushwaha N, 
Morris SJ, Basak A, Ou XM, Albert PR. Impaired repression at a 5-hydroxytryptamine 
1A
 
Serotonin - A Chemical Messenger Between All Types of Living Cells160
receptor gene polymorphism associated with major depression and suicide. The Journal 
of Neuroscience. 2003;23:8788-8799
[5] Santana N, Bortolozzi A, Serrats J, Mengod G, Artigas F. Expression of serotonin 
1A
 and 
serotonin 2A receptors in pyramidal and GABAergic neurons of the reat pre-frontal cor-
tex. Cerebral Cortex. 2004;14:1100-1109. DOI: 10.1093/cercor/bhh070
[6] Day HE, Greenwood BN, Hammack SE, Watkins LR, Fleshner M, Maier SF, Campeau 
S. Differential expression of 5HT-1A, alpha 1b adrenergic, CRFR1, and CRF-R2 receptor 
mRNA in serotonergic, gamma-aminobutyric acidergic, and catecholaminergic cells of 
the rat dorsal raphe nucleus. Journal of Comparative Neurology. 2004;474:364-378. DOI: 
10.1002/cne.20138
[7] Palchaudhuri M, Flugge G. 5-HT
1A
 receptor expression in pyramidal neurons of corti-
cal and limbic brain regions. Cell and Tissue Research. 2005;321:159-172. DOI: 10.1007/
s00441-005-1112-x
[8] Luna-Munguia H, Manuel-Apolinar L, Rocha L, Meneses A. 5-HT
1A
 receptor expression 
during memory formation. Psychopharmacology (Berl). 2005;181:309-318. DOI: 10.1007/
s00213-005-2240-4
[9] Aznavour N, Rbah L, Leger L, Buda C, Sastre JP, Imhof A, Charnay Y, Zimmer L. A 
comparison of in vivo and in vitro neuroimaging of 5-HT
1A
 receptor binding sites in 
the cat brain. Journal of Chemical Neuroanatomy. 2006;31:226-232. DOI: 10.1016/j.
jchemneu.2006.01.006
[10] Parsey RV, Arango V, Olvet DM, Oquendo MA, Van Heertum RL, Mann JJ. Regional 
heterogeneity of 5-HT
1A
 receptors in human cerebellum as assessed by positron emis-
sion tomography. Journal of Cerebral Blood Flow & Metabolism. 2005;25:785-793. DOI: 
10.1038/sj.jcbfm.9600072
[11] Patel TD, Zhou FC. Ontogeny of 5-HT
1A
 receptor expression in the developing hippo-
campus. Brain Research. Developmental Brain Research. 2005;157:42-57. DOI: 10.1016/j.
devbrainres.2005.03.006
[12] Chen Y, Penington NJ. Differential effects of protein kinase C activation on 5-HT
1A
 recep-
tor coupling to Ca2+ and K+ currents in rat serotonergic neurones. Journal of Physiology. 
1996;496:129-137. DOI: 10.1113/jphysiol.1996.sp021670
[13] Jeong HJ, Han SH, Min BI, Cho YW. 5-HT
1A
 receptor-mediated activation of 
G-protein-gated inwardly rectifying K+ current in rat periaqueductal gray neurons. 
Neuropharmacology. 2001;41:175-185. DOI: 10.1016/S0028-3908(01)00062-4
[14] Zimmer L, Riad M, Rbah L, Belkacem-Kahlouli A, Le Bars D, Renaud B, Descarries L. 
Toward brain imaging of serotonin 5-HT1A autoreceptor internalization. Neuroimage. 
2004;22:1421-1426. DOI: 10.1016/j.neuroimage.2004.03.020
[15] Albert PR, Lemonde S. 5-HT
1A
 receptors, gene repression, and depression: Guilt by asso-
ciation. Neuroscientist. 2004;10:575-593. DOI: 10.1177/1073858404267382
Association of 5-HT1A Receptors with Affective Disorders
http://dx.doi.org/10.5772/intechopen.68975
161
[16] Haddjeri N, Ortemann C, de Montigny C, Blier P. Effect of sustained administration 
of the 5-HT receptor agonist 1A flesinoxan on rat 5-HT neurotransmission. European 
Neuropsychopharmacology. 1999;9:427-440
[17] Blier P, Ward NM. Is there a role for 5-HT
1A
 agonists in the treatment of depression? 
Biological Psychiatry. 2003;53:193-203. DOI: 10.1016/S0006-3223(02)01643-8
[18] Adayev T, El-Sherif Y, Barua M, Banerjee P. Agonist stimulation of the serotonin
1A
 
receptor causes suppression of anoxia-induced apoptosis via mitogen-activated protein 
kinase in neuronal HN2-5 cells. Journal of Neurochemistry. 1999;72:1489-1496
[19] Kushwaha N, Albert N. Coupling of 5-HT
1A
 auto-receptors to inhibition of mitogen-acti-
vated protein kinase activation via G beta gamma subunit signaling. European Journal 
of Neuroscience. 2005;21:721-732. DOI: 10.1111/j.1460-9568.2005.03904.x
[20] Adayev T, Ranasinghe B, Banerjee P. Transmembrane signaling in the brain by sero-
tonin, a key regulator of physiology and emotion. Bioscience Reports. 2005;25:363-385. 
DOI: 10.1007/s10540-005-2896-3
[21] Adayev T, Ray I, Sondhi R, Sobocki T, Banerjee P. The G protein-coupled 5-HT
1A
 recep-
tor causes suppression of caspase-3 through MAPK and protein kinase C. Biochimica et 
Biophysica Acta. 2003;1640:85-96. DOI: 10.1016/S0167-4889(03)00023-5
[22] Bromet E, Andrade LH, Hwang I, Sampson NA, Alonso J, Girolamo Gd, Graaf Rd, 
Demyttenaere K, Hu C, Iwata N, Karam AN, Kaur J, Kostyuchenko S, Lépine JP, 
Levinson D, Matschinger H, Medina Mora ME, Oakley Browne M, Posada-Villa J, Viana 
MC, Williams WR, Kessler RC. Cross-national epidemiology of DSM-IV major depres-
sive episode. BMC Medicine. 2011;9:90. DOI: 10.1186/1741-7015-9-90
[23] Dell'Osso L, Carmassi C, Mucci F, Marazziti D. Depression, serotonin and tryptophan. 
Current Pharmaceutical Design. 2016;22:949-954. DOI: 10.2174/138161282266615121410
4826
[24] Aberg-Wistedt A, Hasselmark L, Stain-Malmgren R, Apéria B, Kjellman BF, Mathé AA. 
Serotonergic 'vulnerability' in affective disorder: A study of the tryptophan depletion 
test and relationships between peripheral and central serotonin indexes in citalopram-
responders. Acta Psychiatrica Scandinavica. 1998;97:374-380. DOI: 10.1111/j.1600-
0447.1998.tb10017.x
[25] Jans LAW, Riedel WJ, Markus CR, Blokland A. Serotonergic vulnerability and depres-
sion: Assumptions, experimental evidence and implications Molecular Psychiatry. 
2007;12:522-543. DOI: 10.1038/sj.mp.4001920
[26] Kambeitz JP, Howes OD. The serotonin transporter in depression: Meta-analysis of in 
vivo and post mortem findings and implications for understanding and treating depres-
sion. Journal of Affective Disorders. 2015;186:358-366. DOI: 10.1016/j.jad.2015.07.034
Serotonin - A Chemical Messenger Between All Types of Living Cells162
[27] Reimold M, Batra A, Knobel A, Smolka MN, Zimmer A, Mann K, Solbach C, Reischl G, 
Schwärzler F, Gründer G, Machulla HJ, Bares R, Heinz A. Anxiety is associated with 
reduced central serotonin transporter availability in unmedicated patients with unipolar 
major depression: A [11C]DASB PET study. Molecular Psychiatry. 2008;13:606-613. DOI: 
10.1038/sj.mp.4002149
[28] Nash JR, Sargent PA, Rabiner EA, Hood SD, Argyropoulos SV, Potokar JP, Grasby PM, 
Nutt DJ. Serotonin 5-HT1A receptor binding in people with panic disorder: Positron 
emission tomography study. British Journal of Psychiatry. 2008;193:229-234
[29] He M, Sibille E, Benjamin D, Toth M, Shippenberg T. Differential effects of 5-HT1A recep-
tor deletion upon basal and fluoxetine-evoked 5-HT concentrations as revealed by in 
vivo microdialysis. Brain Research. 2001;902:11-17. DOI: 10.1016/S0006-8993(01)02271-5
[30] Guilloux JP, David DJ, Guiard BP, Chenu F, Reperant C, Toth M, Bourin M, Gardier AM. 
Blockade of 5-HT1A receptors by (+/-)-pindolol potentiates cortical 5-HT outflow, but 
not antidepressant-like activity of paroxetine: Microdialysis and behavioral approaches 
in 5-HT1A receptor knockout mice. Neuropsychopharmacology. 2006;31:2162-2172
[31] Ase AR, Reader TA, Hen R, Riad M, Descarries L. Altered serotonin and dopamine 
metabolism in the CNS of serotonin 5-HT (1A) or 5-HT (1B) receptor knockout mice. 
Journal of Neurochemistry. 2000;75:2415-2426
[32] Heisler LK, Chu HM, Brennan TJ, Danao JA, Bajwa P, Parsons LH, Tecott LH. Elevated 
anxiety and antidepressant-like responses in serotonin 5-HT1A receptor mutant mice. 
Proceedings of the National Academy of Sciences of the United States of America. 
1998;95:15049-15054
[33] Andrews N, Hogg S, Gonzalez LE, File SE. 5-HT1A receptors in the median raphe 
nucleus and dorsal hippocampus may mediate anxiolytic and anxiogenic behaviors 
respectively. European Journal of Pharmacology. 1994;264:259-264
[34] Gonzalez LD, Andrews N. File SE. 5-HT1A and benzodiazepine receptors in the baso-
lateral amygdala modulate anxiety in the social interaction test, but not in the elevated 
plusmaze. Brain Research. 1996;732:145-153
[35] Cervo L, Mocaer E, Bertaglia A, Samanin R. Roles of 5-HT (1A) receptors in the dor-
sal raphe and dorsal hippocampus in anxiety assessed by the behavioral effects of 
8-OH-DPAT and S 15535 in a modified Geller–Seifter conflict model. Neuropharmacology. 
2000;39:1037-1043
[36] De Vry J. 5-HT1A receptor agonists: Recent developments and controversial issues. 
Psychopharmacology (Berl). 1995;121:1-26
[37] Gross C, Zhuang X, Stark K, Ramboz S, Oosting R, Kirby L, Santarelli L, Beck S, Hen R. 
Serotonin1A receptor acts during development to establish normal anxiety-like behav-
iour in the adult. Nature. 2002;416:396-400
Association of 5-HT1A Receptors with Affective Disorders
http://dx.doi.org/10.5772/intechopen.68975
163
[38] Donaldson ZR, Piel DA, Santos TL, Richardson-Jones J, Leonardo ED, Beck SG, 
Champagne FA, Hen R. Developmental effects of serotonin 1A auto-receptors on anxiety 
and social behavior. Neuropsychopharmacology. 2014;39:291-302
[39] Richardson-Jones JW, Craige CP, Nguyen TH, Kung HF, Gardier AM, Dranovsky A, 
David DJ, Guiard BP, Beck SG, Hen R, et al. Serotonin-1A auto-receptors are necessary 
and sufficient for the normal formation of circuits underlying innate anxiety. The Journal 
of Neuroscience. 2011;31:6008-6018
[40] Garcia-Garcia AL, Newman-Tancredi A, Leonardo ED. 5-HT (1A) receptors in mood and anxi-
ety: Recent insights into autoreceptor versus heteroreceptor function. Psycho-pharmacology. 
2014;231:623-636
[41] Albert PR, Francois BL. Modifying 5-HT1A receptor gene expression as a new tar-
get for antidepressant therapy. Frontiers in Neuroscience. 2010;4:35. DOI: 10.3389/
fnins.2010.00035
[42] Bortolozzi A, Castane A, Semakova J, Santana N, Alvarado G, Cortes R, Ferres-Coy A, 
Fernandez G, Carmona MC, Toth M, et al. Selective siRNA-mediated suppression of 
5-HT1A auto-receptors evokes strong anti-depressant-like effects. Molecular Psychiatry. 
2012;17:612-623
[43] Wang L, Zhou C, Zhu D, Wang X, Fang L, Zhong J, Mao Q, Sun L, Gong X, Xia J, Lian 
B, Xie P. Serotonin-1A receptor alterations in depression: A meta-analysis of molecular 
imaging studies. BMC Psychiatry. 2016;16:319. DOI: 10.1186/s12888-016-1025-0
[44] Kaufman J, DeLorenzo C, Choudhury S, Parsey RV. The 5-HT 1A receptor in major 
depressive disorder. European Neuropsychopharmacology. 2016;26:397-410
[45] Okita K, Shiina A, Nakazato M, Iyo M. Tandospirone, a 5-HT1A partial agonist is effec-
tive in treating anorexia nervosa: A case series. Annals of General Psychiatry. 2013;12:7. 
DOI: 10.1186/1744-859X-12-7
[46] Robinson DS, Rickels K, Feighner J, Fabre LF, Gammans RE, Shrotriya RC, Alms DR, 
Andary JJ, Messina ME. Clinical effects of the 5-HT1A partial agonists in depression: 
A composite analysis of buspirone in the treatment of depression. Journal of Clinical 
Psychopharmacology. 1990;10:67S-76S
[47] Sato S, Mizukami K, Asada T. A preliminary open-label study of 5-HT 1A partial agonist 
tandospirone for behavioural and psychological symptoms associated with dementia. 
The International Journal of Neuropsychopharmacology. 2007;10:281-283
[48] Stahl SM. Action mechanism of serotonin selective reuptake inhibitors: Serotonin recep-
tors and pathways mediate therapeutic effects and side effects. Journal of Affective 
Disorders. 1998;51:215-235
[49] Sumiyoshi T, Higuchi Y, Uehara T. Neural basis for the ability of atypical antipsychotic 
drugs to improve cognition in schizophrenia. Frontiers in Behavioral Neuroscience. 
2015;2013. DOI: 10.3389/fnbeh.2013.00140
Serotonin - A Chemical Messenger Between All Types of Living Cells164
[50] Carr GV, Lucki I. The role of serotonin receptor sub-types in treating depression: A 
review of animal studies. Psychopharmacology. 2011;213:265-287
[51] Artigas F. Serotonin receptors involved in antidepressant effects. Pharmacology & 
Therapeutics. 2013;137:119-131
[52] Czopek A, Kołaczkowski M, Bucki A, Byrtus H, Pawłowski M, Siwek A, Bojarski AJ, 
Bednarski M, Wróbel D, Wesołowska A. Novel mannich bases, 5-arylimidazolidine-2,4-
dione derivatives with dual 5-HT1A receptor and serotonin transporter affinity. Archiv 
der Pharmazie. 2013;346:98-109
[53] Waszkielewicz AM, Pytka K, Rapacz A, Wełna E, Jarzyna M, Satała G, Bojarski A, Sapa J, 
Żmudzki P, Filipek B, Marona H. Synthesis and evaluation of antidepressant-like activity 
of some 4-substituted 1-(2-methoxyphenyl) piperazine derivatives. Chemical Biology & 
Drug Design. 2015;85:326-335. DOI: 10.1111/cbdd.12394
[54] Pavlaković G, Tigges J, Crozier TA. Effect of buspirone on thermal sensory and pain 
thresholds in human volunteers. BMC Pharmacology and Toxicology. 2009;9:12
[55] Fulton B, Brogden B. Buspirone: an updated review of its clinical pharmacology, thera-
peutic pharmacology, and therapeutic applications. Adis Drug Evaluation. CNS Drugs. 
1997;7:68-88. DOI: 10.2165/00023210-199707010-00007
[56] Chen JJ. Pharmacologic safety concerns in Parkinson's disease: Facts and insights. 
International Journal of Neuroscience. 2011;121(Suppl 2):45-52. DOI: 10.3109/00207454. 
2011.620193
[57] Díaz-Mataix L, Scorza MC, Bortolozzi A, Toth M, Celada P, Artigas F. Involvement of 
5-HT1A receptors in prefrontal cortex in the modulation of dopaminergic activity: Role 
in atypical antipsychotic action. The Journal of Neuroscience. 2005;25:10831-10843. DOI: 
10.1523/JNEUROSCI.2999-05.2005
[58] Petracca A, Nisita C, McNair D, Melis G, Guerani G, Cassano GB. Treatment of general-
ized anxiety disorder: Preliminary clinical experience with buspirone. The Journal of 
Clinical Psychiatry. 1990;51:31-39
[59] Dimitriou EC, Parashos AJ, Giouzepas JS. Buspirone vs alprazolam: A double-blind 
comparative study of their efficacy, adverse effects and withdrawal symptoms. Drug 
Investigation. 1992;4:316-321. DOI: 10.1007/BF03259411
[60] Pytka K, Zmudzka E, Lustyk K, Rapacz A, Olczyk A, Galuszka A, Waszkielewicz A, 
Marona H, Sapa J, Barbara F. The antidepressant-and anxiolytic-like activities of new 
xanthone derivative with piperazine moiety in behavioral tests in mice. Indian Journal 
of Pharmacology. 2016;48:286
[61] Jenkins SW, Robinson DS, Fabre JR, Andary JJ, Messina ME, Reich IA. Gepirone in the 
treatment of major depression. Journal of Clinical Psychopharmacology. 1990;10:77S-85S
[62] Blier P, de Montigny C. Electrophysiological investigation of the adaptive response 
of the 5-HT system to the administration of 5-HT1A receptor agonists. Journal of 
Cardiovascular Pharmacology. 1990;15:S42-S48
Association of 5-HT1A Receptors with Affective Disorders
http://dx.doi.org/10.5772/intechopen.68975
165
[63] DeVeaugh-Geiss J. Gepirone treatment of generalized anxiety disorder (GAD). 50th 
NCDEU Annual Meeting; June 14-17, 2010; Boca Raton, FL
[64] Rickels K, Schweizer E, DeMartinis N, Mandos L, Mercer C. Gepirone and diaz-
epam in generalized anxiety disorder: A placebo-controlled trial. Journal of Clinical 
Psychopharmacology. 1997;17:272-277
[65] Bielski RJ, Cunningham L, Horrigan JP, Londborg PD, Smith WT, Weiss K. Gepirone 
extended-release in the treatment of adult outpatients with major depressive disorder: 
A double-blind, randomized, placebo-controlled, parallel-group study. The Journal of 
Clinical Psychiatry. 2008;69:571-577
[66] Fabre LF, Clayton AH, Smith LC, Goldstein I, Derogatis LR. The effect of Gepirone-ER in 
the treatment of sexual dysfunction in depressed men. The Journal of Sexual Medicine. 
2012;9:821-829. DOI: 10.1111/j.1743-6109.2011.02624.x
[67] Murata Y, Yanagihara Y, Mori M, Mine K, Enjoji M. Chronic treatment with tandospirone, 
a serotonin 1A receptor partial agonist, inhibits psychosocial stress-induced changes in 
hippocampal neurogenesis and behavior. Journal of Affective Disorders. 2015;180:1-9. 
DOI: http://dx.doi.org/10.1016/j.jad.2015.03.054
[68] Beyer JL, Weisler RH. Adjunctive brexpiprazole for the treatment of major depres-
sive disorder. Expert Opinion on Pharmacotherapy. 2016;17:2331-2339. DOI: 10.1007/
s40263-016-0320-0
[69] Schoeffter P, Hoyer D. Centrally acting hypotensive agents with affinity for 5-HT1A 
binding sites inhibit forskolin-stimulated adenylate cyclase activity in calf hippocam-
pus. British Journal of Pharmacology. 1988;95:975-985
[70] Pitchot W, Wauthy J, Hansenne M, Pinto E, Fuchs S, Reggers J, Legros JJ, Ansseau M. 
Hormonal and temperature responses to the 5-HT1A receptor agonist flesinoxan in nor-
mal volunteers. Psychopharmacology. 2002;164:27-32. DOI: 10.1007/s00213-002-1177-0
[71] Grof P, Joffe R, Kennedy S, Persad E, Syrotiuk J, Bradford D. An open study of oral 
flesinoxan, a 5-HT1A receptor agonist, in treatment-resistant depression. International 
Clinical Psychopharmacology. 1993;8:167-172
[72] Prinsze C, Stevens G. Flesinoxan in the treatment of major depressive disorder: A fixed 
dose, placebo-controlled trial. European Neuropsychopharmacology. 1996;6:S4-S73
[73] Cryan JF, Redmond AM, Kelly JP, Leonard, BE. The effects of the 5-HT 1A agonist 
flesinoxan, in three paradigms for assessing antidepressant potential in the rat. European 
Neuropsychopharmacology. 1997;7:109-114. DOI: 10.1016/S0924-977X(96)00391-4
[74] Hjorth S, Magnusson T. The 5-HT 1A receptor agonist, 8-OH-DPAT, preferentially 
activates cell body 5-HT auto-receptors in rat brain in vivo. Naunyn-Schmiedeberg's 
Archives of Pharmacology. 1988;338:463-471. DOI: 10.1007/BF00179315
[75] Thase ME, Chen D, Edwards J, Ruth A. Efficacy of vilazodone on anxiety symptoms 
in patients with major depressive disorder. International Clinical Psychopharmacology. 
2014;29:351-356. DOI: 10.1097/YIC.0000000000000045
Serotonin - A Chemical Messenger Between All Types of Living Cells166
[76] Mathews M, Gommoll C, Chen D, et al. Efficacy and safety of vilazodone 20 and 40 mg 
in major depressive disorder: A randomized, double-blind, placebo-controlled trial. 
International Clinical Psychopharmacology. 2015;30:67-74. DOI: 10.1097/YIC.00000000000 
00057
[77] Durgam S, Gommoll C, Forero G, Nunez R, Tang X, Mathews M, Sheehan DV. Efficacy 
and safety of vilazodone in patients with generalized anxiety disorder: A randomized, 
double-blind, placebo-controlled, flexible-dose trial. The Journal of Clinical Psychiatry. 
2016;77:1687-1694. DOI: 10.4088/JCP.15m09885
[78] Khan A, Durgam S, Tang X, Ruth A, Mathews M, Gommoll CP. Post hoc analyses of 
anxiety measures in adult patients with generalized anxiety disorder treated with 
vilazodone. The Primary Care Companion for CNS Disorders. 2016;18(2). DOI: 10.4088/
PCC.15m01904
[79] Ashby Jr CR, Kehne JH, Bartoszyk GD, Renda MJ, Athanasiou M, Pierz KA, Seyfried 
CA. Electrophysiological evidence for rapid 5-HT₁A autoreceptor inhibition by vilazo-
done, a 5-HT₁A receptor partial agonist and 5-HT reuptake inhibitor. European Journal 
of Pharmacology. 2013;714:359-365. DOI: 10.1016/j.ejphar.2013.07.014
[80] Page ME, Cryan JF, Sullivan A, Dalvi A, Saucy B, Manning DR, Lucki I. Behavioral 
and neurochemical effects of 5-{4-[4-(5-Cyano-3-indolyl)-butyl)-butyl]-1-piperazinyl}-
benzofuran-2-carboxamide (EMD 68843): A combined selective inhibitor of sero-
tonin reuptake and 5-hydroxytryptamine
1A
 receptor partial agonist. Journal of 
Pharmacology and Experimental Therapeutics. 2002;302(3):1220-1227. DOI: 10.1124/
jpet.102.034280
[81] Adamec R, Bartoszyk GD, Burton P. Effects of systemic injections of vilazodone, a selec-
tive serotonin reuptake inhibitor and serotonin 1A receptor agonist, on anxiety induced 
by predator stress in rats. European Journal of Pharmacology. 2004;504:65-77. DOI: 
10.1016/j.ejphar.2004.09.009
[82] de Paulis T. Drug evaluation: Vilazodone—A combined SSRI and 5-HT1A partial ago-
nist for the treatment of depression. IDrugs. 2007;10:193-201
[83] Rodríguez-Landa JF, Bernal-Morales B, Gutiérrez-García AG. Estrés, miedo, ansie-
dad y depresión. En: Coria-Ávila GA, editor. Neurofisiología de la conducta. Xalapa: 
Universidad Veracruzana; 2012. pp. 136-165. ISBN: 978-607-502-191-1
[84] Valuck RJ, Libby Am, Anderson HD, Allen RR, Strombon I, Marangell LB, Perahia D. 
Comparison of antidepressant classes and the risk and the course of suicide attempts 
in adults: Propensity matched, retrospective cohort study. British Journal of Psychiatry. 
2016;208:271-279. DOI: 10.1192/bjp.bp.114.150839
[85] Chuang HY, Chang YH, Cheng LY, Wang YS, Chen SL, Chen SH, Chu CH, Lee IH, Chen 
PS, Yeh TL, Yang YK, Lu RB. Venlafaxine, paroxetine and milnacipran for major depres-
sion disorders: A pragmatic 24-week study. Chinese Journal of Physiology. 2014;57:265-
270. DOI: 10.1111/j.1365-2710.2007.00828.x
Association of 5-HT1A Receptors with Affective Disorders
http://dx.doi.org/10.5772/intechopen.68975
167
[86] Mokhber N, Abdollahian E, Soltanfar A, Samadi R, Saghebi A, Haghighi MB, Azarpazhooh 
A. Comparison of sertraline, venlafaxine and desipramine effects on depression, cog-
nition and the daily living activities in Alzheimer patients. Pharmacopsychiatry. 
2014;47:131-140. DOI: 10.1055/s-0034-1377041
[87] Amsterdam JD, Lorenzo-Luaces L, Soeller I, Li SQ, Mao JJ, DeRubeis RJ. Short-term 
venlafaxine v. lithium monotherapy for bipolar type II major depressive episodes: 
Effectiveness and mood conversion rate. British Journal of Psychiatry. 2016;208:359-365. 
DOI: 10.1192/bjp.bp.115.169375
[88] Clayton AH, Tourian KA, Focht K, Hwang E, Cheng RJ, Thase ME. Desvenlafaxine 500 
and 100 mg/d versus placebo for treatment of major depressive disorder: A phase 4, 
randomized controlled trial. The Journal of Clinical Psychiatry. 2015;76:562-569. DOI: 
10.4088/JCP.13m08978
[89] Carrasco JL, Kornstein SG, McIntyre RS, Fayyard R, Prieto R, Salas M, Mackell J, Boucher 
M. An integrated analysis of the efficacy and safety of desvenlafaxine in the treatment of 
major depressive disorder. International Clinical Psychopharmacology. 2016;31:134-146. 
DOI: 10.1097/YIC.0000000000000121
[90] Huang Q, Zhong X, Yun Y, Yu B, Huang Y. Efficacy and safety of multiple doses of 
levomilnacepran extended-release for the treatment of major depressive disorder. 
Neuropsychiatric Disease and Treatment. 2016;12:2707-2714. DOI: 10.2147/NDT.S114955
[91] Higuchi T, Kamijima K, Nakagome K, Itamura R, Asami Y, Kuribayashi K, Imaeda T. 
A randomized, double-blinded, placebo-controlled study to evaluate the efficacy and 
safety of venlafaxine extended release and long-term extension study for patients 
with major depressive disorder in Japan. International Clinical Psychopharmacology. 
2016;31:8-19. DOI: 10.1097/YIC.0000000000000105
[92] Xu Y, Bai SJ, Lan XH, Qin B, Huang T, Xie P. Randomized controlled trials of serotonin-
norepinephrine reuptake inhibitors in treating major depressive disorder in children and 
adolescents: A meta-analysis of efficacy and acceptability. Brazilian Journal of Medical 
and Biological Research. 2016;49:e4806. DOI: 10.1590/1414-431X20164806
[93] Cipriani A, Zhou X, Giovane C, Hetrick SE, Qin B, Whittington C, Coghill D, Zhang 
Y, Hazell P, Leucht S, Cuijpers P, Pu J, Cohen D, Ravindran AV, Liu Y, Michael KD, 
Yang L, Liu L, Xie P. Comparative efficacy and tolerability of antidepressants for major 
depressive disorder in children and adolescents: A network meta-analysis. The Lancet. 
2016;388:881-890. http://dx.doi.org/10.1016/S0140-6736(16)30385-3
[94] Rodríguez-Landa JF, Puga-Olguín A, Germán-Ponciano LJ, García-Ríos RI, Soria-
Fregozo C. Anxiety in natural and surgical menopause—Physiologic and therapeutic 
bases. In: Durbano F, editor. A Fresh Look Anxiety Disorders. Rijeka: InTech; 2015. pp. 
173-198. http://dx.doi.org/10.5772/6062
[95] Joffe H, Soares CN, Petrillo LF, Viguera AC, Somley BL, Koch JK, Cohen LS. Treatment 
of depression and menopause-related symptoms with the serotonin-norepinephrine 
reuptake inhibitor duloxetine. Journal of Clinical Psychiatry. 2007;68:943-950
Serotonin - A Chemical Messenger Between All Types of Living Cells168
[96] Freeman MP, Hirschberg AH, Wang B, Petrillo LF, Connors S, Regan S, Joffe H, Cohen 
L. Duloxetine for major depressive disorder and daytime and nighttime hot flashes 
associated with the menopause transition. Maturitas. 2013;75:170-174. DOI: 10.1016/j.
maturitas.2013.03.007
[97] Kornstein SG, Pedersen RD, Holland PJ, Nemeroff CB, Rotschild AJ, Thase ME, Trivedi 
MH, Ninan PT, Keller MB. Influence of sex and menopause status on response, remis-
sion, and recurrence in patients with recurrent major depressive disorder treated with 
venlafaxine extended release or fluoxetine: Analysis of data from the PREVENT study. 
The Journal of Clinical Psychiatry. 2014;75:62-68. DOI: 10.4088/JCP.12m07841
[98] Kornstein SG, Clayton AH, Bao Weihang, Guico-Pabia CJ. A pooled analysis of the 
efficacy of desvenlafaxine for the treatment of major depressive disorder in perimeno-
pausal and postmenopausal women. Journal of Women's Health. 2015;24:281-290. DOI: 
10.1089/jwh.2014.4900
[99] Kendler KS, Gatz M, Gardner CO, Pedersen NL. A Swedish national twin study of life-
time major depression. Journal of Clinical Psychiatry. 2006;163:109-114. DOI: http://
dx.doi.org/10.1176/appi.ajp.163.1.109
[100] Polter AM, Li X. 5-HT1A receptor-regulated signal transduction pathways in brain. 
Cell Signal. 2010;22:1406-1412. DOI: 10.1016/j.cellsig.2010.03
[101] Riad M, Zimmer L, Rbah L, Watkins KC, Hamon M, Descarries L. Acute treatment with 
the antidepressant fluoxetine internalizes 5-HT1A auto-receptors and reduces the In 
vivo binding of the PET radioligand [18F] MPPF in the nucleus raphe dorsalis of rat. 
Journal of Neuroscience. 2004;4:5420-5426. DOI: 10.1523/JNEUROSCI.0950-04.2004
[102] Rossi DV, Burke TF, McCasland M, Hensler JG. Serotonin-1A receptor function in 
the dorsal raphe nucleus following chronic administration of the selective serotonin 
reuptake inhibitor sertraline. Journal of Neurochemistry. 2008;105:1091-1099. DOI: 
10.1111/j.1471-4159.2007.05201.x
[103] Murakami M, Osaka K, Ichibayashi H, Mizuno H, Ochiai T, Ishida M, Alev L, Nishioka 
K. An open-label, long-term, phase III extension trial of duloxetine in Japanese patients 
with fibromyalgia. Modern Rheumatology 2016; 31:1-8. http://dx.doi.org/10.1080/1439
7595.2016.1245237
[104] Häuser W, Ablin J, Perrot S, Fitzcharles MA. Management of fibromyalgia: practi-
cal guides from recent evidence-based guidelines. Polish Archives of Medicine 2017; 
127(1):47-56. DOI: 10.20452/pamw.3877.
[105] Ravishankar V, Chowdappa SV, Benegal V, Muralidharan K. The efficacy of atomixetine 
in treating adult attention deficit hyperactivity disorder (ADHD): a meta-analysis of 
controlled trial. Asian Journal of Psychiatry 2016; 24:53-58. DOI: 10.1016/j.ajp.2016.08.017
[106] Gayleard JL, Mychailyszyn MP. Atomoxetine treatment for children and adoles-
cents with attention-deficit/hyperactivity disorder (ADHD): a comprehensive meta-
analysis of outcomes on parent-related core symptomatology. Attention Deficit and 
Hyperactivity Disorders 2017; In press. DOI: 10.1007/s12402-01716-y.
Association of 5-HT1A Receptors with Affective Disorders
http://dx.doi.org/10.5772/intechopen.68975
169
[107] McElroy SL, Frye MA, Altshuler LL, Suppes T, Hellemann G, Black D, Mintz J, Kupka 
R, Nolen W, Leverich GS, Denicoff KD, Post RM, Keck E. A 24-week, randomized, con-
trolled trial of adjunctive sibutramine versus topiramate in the treatment of weigth gain 
in overweight or obese patients with bipolar disorder. Bipolar Disorders 2007; 9:426-434. 
DOI: 10.1111/j.1399-5618.2007.00488.x
[108] Lee YH, Song GG. Comparative efficacy and tolerability of duloxetine, pregabalin, and 
milnacipran for treatment of fibromyalgia: a Bayesian network meta-analysis of ran-
domized control trial. Rheumatology International 2016;36(5):663-672. DOI: 10.1007/
s00296-016-3468-5.
Serotonin - A Chemical Messenger Between All Types of Living Cells170
